UK Tech Firm Launches Covid & Vaccination Passport

MANCHESTER, UK, Dec 4, 2020 – (ACN Newswire) – British technology company VST Enterprises has today confirmed it has developed the worlds first secure 5 In 1 digital health passport and wallet. V-Health Passport(TM) is a crucial 'safe technology enabler' in reviving global economies, home lives and helping Governments, business and industry to start returning to work and normality.











The cross border, cross corporation V-Health Passport(TM) can be used by international Governments, consumers and companies to authenticate a persons true identity, their Covid test results and vaccinations. This 'enabler' allows them to prove their test and/or vaccination status. Uniquely the V-Health Passport(TM) has its own contact tracing capability using anonymised data, whilst also protecting citizens data and privacy with a concept in the vein of 'self sovereign identity'.

Manchester headquartered VSTE have innovated the V-Health Passport(TM) to be the most secure digital health passport and wallet in the world, but at the same time multi functional and future proof to deal with all future pandemics;

The V-Health Passport(TM) has 5 key 'enabling' features to its technology;

– Powered by the worlds most secure cyber security coding technology VCode(R) it is the worlds most secure 'next generation' code scanning technology using a closed loop system with end to end encryption and 2.2 Quintillion collision free codes (A VCode(R) can only exist once due to being encoded from a centralised system).
– V-Health Passport(TM) is a test agnostic system so it can record results from all global Covid testing manufacturers and protocols from PCR to rapid antigen and antibody testing.
– V-Health Passport(TM) also has its own unique contact tracing capability 'True Contact(TM)' built within the technology designed for travel, sports stadiums, venues, factories, offices and construction sites.
– The ultra-secure platform can now also hold vaccination records of all the major vaccination manufacturers which will be crucial in a person validating they have been vaccinated, the vaccine type, batch, dosage and date.
– Uniquely V-Health Passport(TM) is the only health wallet and cross border platform in the world that is multi-functional and GDPR compliant. It allows acts like 'self sovereign identity', meaning a citizens personal data is protected and they choose what they want to share and with whom they want to interact or authorise.

But at the same time tech boss Louis-James Davis – CEO of VST Enterprises warned of the potential dangers and reliance on using QR code scanning technology within any form of health passport for airline travel or entry into a venue or workplace which could lead to potential security breaches of personal data and information.

It follows the hack and breach earlier this year of the former Australian Prime Minister Tony Abbot whose Quantas airline boarding card was hacked and details revealed including his passport number, mobile phone number and Qantas airline messages referring to the former PM.

Louis-James Davis went on to state that both bar codes and QR codes – which represent first and second generation technology – are unsecure and vulnerable to hacking.

"QR codes were originally developed as a scanning technology for close proximity car parts tracking, a world away from Identity and banking use cases and now digital health passports. It was then used to skip the input of websites in marketing and promotional purposes. They were simply never designed with security or privacy in mind… they are simply not fit for purpose and should not be used at all in any form for delivery of sensitive information, travel or event tickets or health passport. QR codes can be subject to a process called 'Attagging or 'cloning.' Louis-James Davis said.

Davis also warned that the public will not tolerate breaches of their personal data and information along with their already existing and heightened concerns over privacy during the pandemic. He continued;

"Attagging is where a 'genuine QR code' is replaced by a 'cloned QR code' which then redirects the person scanning that code to a similar website where personal data can be intercepted and breached. The problem is that serious that in India alone there are over 1 BILLION fraudulent financial transactions each day using QR codes. As the scanning user journey is the same, it is only tech savvy individuals that may notice the domain name has changed."

As reported by a recent Forbes Magazine investigation, it is predicted that over 11 Million households in the US alone will scan a QR code this year and the majority of them, some 71% of people who have interacted with a QR code will not know if it is the start of a malicious hack. It is envisaged that over 5.3 Billion QR codes will be redeemed this year making it one of the fastest growing tech scanning interactions and also posing one of the greatest cyber threats.

QR codes can be cloned and redirected to other information points or websites. Often criminals and hackers will exploit this by putting a fake QR code over a genuine QR code. So a QR code for example on scanning would link to the genuine website www.similardomain.com but a fake QR code can be made up printed off and placed over the genuine code to redirect to www.similar-domain.com at this point the member of the public is tricked into entering their personal information, private data and financial information. The rogue website looks and feels exactly like the genuine one and is made to mirror it precisely.

VCode(R) which is the ultra secure digital code which powers the V-Health Passport(TM) cannot be cloned. Even if it was printed off, or a photograph was taken and placed over a VCode(R) or V-Health Passport(TM) it simply wont scan as it works on a call and response system of information between the code and web platform to verify location of the code, user ID and time and date and much more."

Louis-James Davis said; "We developed and built the V-Health Passport and health wallet to be the most secure technology on the planet that you could use as a health passport where you could combine your test status, vaccination record, boarding pass, airline ticket, music or sports ticket all in one app.

With V-Health Passport(TM) we wanted to provide functionality and greater mobility to allow citizens to return to work, be fit to fly or return to the sports stadiums. But at the heart of the technology was the ability to protect and respect data privacy of the individual.

The lack of engagement and interaction by the public with Government track and trace app/s over the pandemic was over privacy, security of data and the tracking of a persons live location. This is why we have built a unique system in the vein of 'Self Sovereign ID' with the ethics of privacy & security by design. The V-Health Passport(TM) puts the citizen in control in a way which they share information with who, when and where."

By having a technology health wallet which confirms your Covid test status and your vaccination record/s it then becomes a 'safe technology enabler' to assist Governments, companies, consumers and organisations to resume greater mobility and returning life back to normality. But critically this technology will help revive and restore economic prosperity.

V-Health Passport(TM) will help employers safely return their employees back to their offices, factories and warehouses. It will facilitate airlines to allow their passengers to be fit to fly and avoid the need for quarantine restrictions. At the same time it will ensure their airline ticket or boarding pass is secure and won't be hacked.

V-Health Passport(TM) will allow sports fans to return to the stadiums at capacity and not at the current socially distanced crowd protocols of 2000 fans. It will help get the hospitality sector back on its feet welcoming customers back. Because of the way V-Health Passport(TM) is designed – based on interaction and incentive – the hospitality sector can engage with with unique offerings and discounts to its customers.

V-Health Passport(TM) will help the Live music and entertainment sectors resume their concerts and performances in arenas, stadiums and theatres. They will be safe in the knowledge that fans have either been tested or vaccinated and can authenticate their status.

A citizen will be able to share their health pass and confirm their Covid test status, or present their vaccination record. They will also be able to show their credit score, work permit or visa, scan their travel or event pass. At the heart of each interaction they will have peace of mind that their data and information is highly secure and ultimately, they control who sees what, who scans what, where and when.

For more information on V-HEALTH PASSPORT(TM).
https://v-healthpassport.co.uk

For more information on VCode(R) and VPlatform(R) technology please visit
https://www.vstenterprises.com

For all media enquiries
Please contact Gerard Franklin – Head Of Communications & External Relations
M: 07885 388398 e: gerard@vstenterprises.com
VST Enterprises Ltd | The Lexicon | Mount Street | Manchester | M2 5NT

SOURCE: VST Enterprises Ltd & VHealth Passport

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

BioVaxys Provides Viral Vaccine Platform Program Update

Vancouver, BC, Dec 1, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. BioVaxys scientists also observed a clear dose-response, with lower levels of antibodies induced by the two lowest doses tested of 0.3ug and 1ug (median titers 1:59 and 1:124, respectively), and with significantly higher antibody levels with the two highest doses tested of 3ug and 10ug (median titers 1:4800 and 1:9430, respectively). No toxicity was noted in mice at any dose level.

Dr. David Berd, the Chief Medical Officer of BioVaxys, stated, "Antibody titer is the usual way of measuring the amount of an antibody in the blood or a mouse or a human subject. It is determined by serially diluting a serum sample to reach the point where antibody is no longer detectable. An antibody titer of 1:9430 means that the serum sample could be diluted up to 9000-fold and still retain biologic activity. In human subjects who had recovered from Covid-19, antibody titers were between 1:100 and 1:1000."

The preclinical study (also known as the "murine model study"), which began in September 2020 and was conducted by leading independent contract research organization Charles River Laboratories, Inc. under contract with BioVaxys, evaluated the anti-virus immune response elicited by BVX-0320 in a controlled murine model by measuring the development of antibodies to the protein that binds the virus to human cells. Previous results from the preclinical study show that BVX-0320 elicits a 96.4% positive immune response against the SARS-CoV-2 s-spike protein in a formulation not requiring an extraordinary cold-chain; the titer analysis confirms that 100% of vaccinated mice in all but the lowest dose group had a positive immune response against the SARS-CoV-2 s-spike protein.

BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization "teaches" a patient's immune system to recognize and make target proteins more 'visible' as foreign, thereby stimulating an immune response. The haptenization of viral proteins imparts BioVaxys with the flexibility of a 'cassette-type' approach not possible with other vaccines, where they can "drop in" or "swap" the appropriate viral antigen(s) for haptenization and the creation of a new vaccine, potentially allowing for faster development timelines relative to other vaccine approaches.

Kenneth Kovan, co-founder, President & Chief Operating Officer of BioVaxys, says that, "The 100% efficacy seen across higher dose levels in the animal study, safety profile, dose-response, and formulation present a very promising emerging profile for BVX-0320. The preclinical data also supports our corporate strategy of expanding this haptenized viral protein vaccine platform across a range of viral diseases, which we are actively pursuing. Our approach is generating interest as it appears to be ideally suited for quickly addressing emerging viruses."

The Company is in preliminary discussions with third parties on potential collaborations under which BioVaxys would create new vaccines for a range of viral diseases based on haptenizing different viral proteins. BioVaxys co-founder and CEO James Passin stated that, "The results from our Covid-19 vaccine study are highly encouraging and support our view on the scientific and commercial merits of our haptenized viral protein vaccine technology platform; we hope to leverage these encouraging results to accelerate ongoing partnership discussions."

Data from additional analysis by BioVaxys is imminent, including the measurement of post-vaccination T-cell response. This consists of stimulating T-cells obtained from the same mice with viral peptides and measuring the degree of T-cell activation using the established analytical method of flow cytometry and the production of cytokines, including IL-2 and gamma interferon.

In a separate study under BioVaxys' collaboration with The Ohio State University Wexner Medical Center, the mouse sera collected from the test animals will be tested for ability to inactivate live SARS-Cov-2 virus. Results are anticipated in the coming weeks.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp., a British Columbia-registered biotechnology company, is a world leader in haptenized protein vaccines that is developing viral and oncology vaccine platforms as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FSE: 5LB).

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

Media Contacts
Andrea Vuturo
+1 508 301 3774
biovaxys@dittopr.co

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs' vaccines will not prove to be effective and/or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69117

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

BioVaxys Provides Viral Vaccine Platform Program Update

Vancouver, BC, Nov 30, 2020 – (ACN Newswire) – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. BioVaxys scientists also observed a clear dose-response, with lower levels of antibodies induced by the two lowest doses tested of 0.3ug and 1ug (median titers 1:59 and 1:124, respectively), and with significantly higher antibody levels with the two highest doses tested of 3ug and 10ug (median titers 1:4800 and 1:9430, respectively). No toxicity was noted in mice at any dose level.

Dr. David Berd, the Chief Medical Officer of BioVaxys, stated, "Antibody titer is the usual way of measuring the amount of an antibody in the blood or a mouse or a human subject. It is determined by serially diluting a serum sample to reach the point where antibody is no longer detectable. An antibody titer of 1:9430 means that the serum sample could be diluted up to 9000-fold and still retain biologic activity. In human subjects who had recovered from Covid-19, antibody titers were between 1:100 and 1:1000."

The preclinical study (also known as the "murine model study"), which began in September 2020 and was conducted by leading independent contract research organization Charles River Laboratories, Inc. under contract with BioVaxys, evaluated the anti-virus immune response elicited by BVX-0320 in a controlled murine model by measuring the development of antibodies to the protein that binds the virus to human cells. Previous results from the preclinical study show that BVX-0320 elicits a 96.4% positive immune response against the SARS-CoV-2 s-spike protein in a formulation not requiring an extraordinary cold-chain; the titer analysis confirms that 100% of vaccinated mice in all but the lowest dose group had a positive immune response against the SARS-CoV-2 s-spike protein.

BioVaxys has developed its vaccine technology platforms based on the established immunological concept that modifying proteins with simple chemicals called haptens makes them more visible to the immune system. The process of haptenization "teaches" a patient's immune system to recognize and make target proteins more 'visible' as foreign, thereby stimulating an immune response. The haptenization of viral proteins imparts BioVaxys with the flexibility of a 'cassette-type' approach not possible with other vaccines, where they can "drop in" or "swap" the appropriate viral antigen(s) for haptenization and the creation of a new vaccine, potentially allowing for faster development timelines relative to other vaccine approaches.

Kenneth Kovan, co-founder, President & Chief Operating Officer of BioVaxys, says that, "The 100% efficacy seen across higher dose levels in the animal study, safety profile, dose-response, and formulation present a very promising emerging profile for BVX-0320. The preclinical data also supports our corporate strategy of expanding this haptenized viral protein vaccine platform across a range of viral diseases, which we are actively pursuing. Our approach is generating interest as it appears to be ideally suited for quickly addressing emerging viruses."

The Company is in preliminary discussions with third parties on potential collaborations under which BioVaxys would create new vaccines for a range of viral diseases based on haptenizing different viral proteins. BioVaxys co-founder and CEO James Passin stated that, "The results from our Covid-19 vaccine study are highly encouraging and support our view on the scientific and commercial merits of our haptenized viral protein vaccine technology platform; we hope to leverage these encouraging results to accelerate ongoing partnership discussions."

Data from additional analysis by BioVaxys is imminent, including the measurement of post-vaccination T-cell response. This consists of stimulating T-cells obtained from the same mice with viral peptides and measuring the degree of T-cell activation using the established analytical method of flow cytometry and the production of cytokines, including IL-2 and gamma interferon.

In a separate study under BioVaxys' collaboration with The Ohio State University Wexner Medical Center, the mouse sera collected from the test animals will be tested for ability to inactivate live SARS-Cov-2 virus. Results are anticipated in the coming weeks.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

About BioVaxys Technology Corp.

Based in Vancouver, BioVaxys Technology Corp., a British Columbia-registered biotechnology company, is a world leader in haptenized protein vaccines that is developing viral and oncology vaccine platforms as well as immuno-diagnostics. The Company is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology, and is planning a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for ovarian cancer. Also in development is a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. BioVaxys has two issued US patents and two patent applications related to its cancer vaccine, and pending patent applications for its SARS-CoV-2 (Covid-19) vaccine and diagnostic technologies. BioVaxys common shares trade on the CSE under the stock symbol "BIOV" and are listed on the Frankfurt Bourse (FSE: 5LB).

ON BEHALF OF THE BOARD
Signed "James Passin"
James Passin, CEO
+1 646 452 7054

Media Contacts
Andrea Vuturo
+1 508 301 3774
biovaxys@dittopr.co

Cautionary Statements Regarding Forward Looking Information

This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, without limitation, statements relating the future operating or financial performance of the Company, are forward looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this news release relate to, among other things, completion of the murine model study, regulatory approval for a Phase I study of its BVX-0320 Vaccine Candidate in humans and the overall development of BioVaxys' vaccines, including any haptenized SARS-Cov-2 protein vaccine. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those expressed or implied in such forward-looking statements.

These forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates, primarily the assumption that BioVaxys will be successful in developing and testing vaccines, that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies including, primarily but without limitation, the risk that BioVayxs' vaccines will not prove to be effective and/or will not receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about whether its products will complete the long, complex and expensive clinical trial and regulatory approval process for approval of new drugs necessary for marketing approval, uncertainty about whether its autologous cell vaccine immunotherapy can be developed to produce safe and effective products and, if so, whether its vaccine products will be commercially accepted and profitable, the expenses, delays and uncertainties and complications typically encountered by development stage biopharmaceutical businesses, financial and development obligations under license arrangements in order to protect its rights to its products and technologies, obtaining and protecting new intellectual property rights and avoiding infringement to third parties and their dependence on manufacturing by third parties.

The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69117

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Sino Biopharmaceutical Announces 2020 Third Quarterly Results

HONG KONG, Nov 30, 2020 – (ACN Newswire) – Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2020 (the "review period"). During the review period, the Group accelerated new drug development and established an internet ecosystem to strategically pursue its transformation by capturing opportunities arising from industry policies. These efforts were reflected in significant sales growth from new products of 66.9% to RMB6.66 billion, marking a step forward in its transformation.

Development Highlights
– The Group has achieved considerable sales growth from a number of new products and oncology products, with sales from new products soaring by 66.9% to RMB6.66 billion, representing 36.7% of the total revenue.
– The proportion of innovative medicines increased from approximately 20% same period last year to approximately 25%, and a large number of important products will be launched soon.
– Sales of oncology medicines amounted to approximately RMB 5,792.06 million, an increase of approximately 37.8% over the same period last year.
– Satisfactory progress in R&D has been achieved and 11 new production approvals were obtained. For the nine months ended 30 September 2020, the total R&D expenditure accounted for approximately 11.6% of the Group's revenue.
– The Group had 13 newly launched products in 2018, 26 newly launched products in 2019, and has 26 newly launched products since 2020.
– The Group has facilitated convenient communications between doctors and patients via various Internet platforms. It has also commenced Internet marketing activities through a number of qualified platforms, reaping satisfactory results.
– The Group's member company, CT Tianqing, has achieved a top 20 ranking on the list of "Top 100 Pharmaceutical Enterprises in China" by China National Pharmaceutical Industry Information Center for the sixth consecutive year. It has also been named "Chinese Pharmaceutical Enterprise with the Best Drug Pipeline in 2020".
– Sino Biopharmaceutical has been ranked 2nd on the "Top 100 Chemical Pharmaceutical Enterprises" among the "2019 Top 100 Series of Pharmaceutical Industries in China", which was announced during the "2020 National Pharmacy Week, China Pharmaceutical Industry Top 100 Annual Conference, and China Pharmaceutical Internet Economy Annual Conference".

Results
During the review period, the Group recorded revenue of approximately RMB18.13 billion (9M2019: RMB19.32 billion). The proportion of new product sales to total revenue increased from approximately 20.6% in the same period last year to approximately 36.7% during the review period. Profit attributable to the owners of the parent was approximately RMB1.85 billion (9M2019: RMB2.26 billion). Basic earnings per share were approximately RMB9.81 cents (9M2019: RMB11.95 cents). Excluding the impact of amortization expenses of new identifiable intangible assets arising from the acquisition of 24% interests in Beijing Tide (net of related deferred tax and non-controlling interests), the unrealized fair value losses (net) on equity investments and financials assets, as well as the fair value loss of Convertible Bond embedded derivative component and effective interest expenses of Convertible Bond debt component, underlying profit would have been approximately RMB2.29 billion (9M2019: RMB2.60 billion). Based on underlying profit, the earnings per share were approximately RMB12.16 cents (9M2019: RMB13.77 cents). The Group has maintained a strong financial position with cash and bank balances reaching approximately RMB16.10 billion at the period end.

The Board of Directors declared a quarterly dividend of HK2 cents per share. Together with the first quarterly dividend of HK2 cents per share and the second quarterly dividend of HK2 cents paid, the total dividend of the three quarters amounted to HK6 cents per share (9M2019: 6 cents).

COVID-19 hits the whole world, industry policies expedite business reform
During the review period, the pandemic crisis remained far from over. However, China has implemented strict anti-epidemic measures, production and businesses gradually returns to normal. As a result, the number of outpatients and inpatients began to climb, resulting in the improvement in drug sales.

The government published several documents to establish a tiered diagnosis and treatment model, and partnerships between medical institutions operating, so as to facilitate initial consultations at the lower tier. To encourage "Internet + Health Care" and medical informatization, restrictions on the coverage of online consultations have been further relaxed, trying to include eligible medical services in the medical insurance reimbursement list.

The government also intensified its reforms of medical expenses control. At the diagnosis end, national trials of multiple-payment models such as Diagnosis-Related Groups payment or disease category-based payment have commenced. Measures for managing essential drugs covered by medical insurance have also been published to enhance pertinent controls. Also, the third centralized drug procurement program has been expanded to cover a greater variety of drugs, with average prices down by 53%, and some even falling by more than 90%. In expanding the coverage of the centralized drug procurement program, establishing its relevant methodology, and making it a regular practice, competition will intensify, profitability and product structure of the industry will be notably impacted, reform of drug sales and marketing model will accelerate, and the business landscape will be polarized.

Adjustments to the National Reimbursement Drug List ("NRDL") have also commenced, which marks the beginning of dynamic adjustments of the list to come. Innovative drugs and oncology drugs have higher chances to be included quickly. As the NRDL expands its coverage, the coverage for outpatient reimbursement will also be expanded, hence, accessibility to and fairness of the products above are likely to be enhanced.

During the review period, the National Medical Products Administration published three technical documents, including the Working Procedures for the Review and Approval of Breakthrough Therapy Designed Drugs (for Trial Implementation) to expedite the filing and assessment of innovative drugs, and facilitate the implementation of the assessment and approval policy that encourage innovation.

Pursue product mix transformation in response to policy changes
During the review period, with a rebound in the number of hospitalized patients, the Group gradually resumed its work on sales of pharmaceutical products. Also, implementation of the third round of the centralized drug procurement program, which covered a number of the Group's key products in the hepatitis, cardio-vascular and analgesic therapeutic areas, had differing effects on sales of the Group's various products. For newly approved products such as the oncology medicines, Qingkeshu, Anxian, Jizhi, and Weishou; the respiratory system medicine, Tianqingsuchang; the cardio-vascular medicines, Anbeining, Taishule, Anxinfen and Beilishu; and the osteoarthritis medicines, Taiyan and Sulibao, their sales volume have increased rapidly following implementation of the centralized drug procurement program.

The Group actively addressed the impact of centralized drug procurement on its sales cost structure by quickly shifting academic and promotion investments to new products, as well as by building a strong sales portfolio of the selected products and their associated products that are able to capitalize on the centralized drug procurement program. The results from such strategies were encouraging. The Group's new oncology medicines, Anxian, Yinishu, Leweixin, Yijiu, and Qingkeyi; antiemetic medicine associated with chemotherapy, Shanqi; new analgesic medicines, Fenkexin and Yu'an; new anti-infective medications, Tianming, Kangsuping, Fengruineng, and Yiruida; and contrast agents, Xian'ai and Qingliming, all delivered robust results.

Sales transformation by building Internet ecosystem
Amid the pandemic, the Group has facilitated convenient communications between doctors and patients via various Internet platforms. In addition, it has stepped up efforts in chronic disease management of the cardio-vascular, respiratory, analgesic, hepatitis and oncology therapeutic areas to enhance patients' professional knowledge and awareness of product applications. It has also commenced Internet marketing activities through a number of qualified platforms, reaping satisfactory results.

R&D
During the review period, satisfactory results were achieved in R&D. During the third quarter, the Group was granted 6 clinical trial approvals, 11 production approvals, and 15 approvals for Consistency Evaluation, and made 6 clinical trial applications, 6 applications for Consistency Evaluation and 2 production applications. Cumulatively, a total of 398 pharmaceutical products had obtained clinical trial approval, or were under clinical trial or applying for production approval. Out of these, 37 were for hepatitis medicines, 190 for oncology medicines, 22 for respiratory system medicines, 20 for endocrine, 16 for cardio-cerebral medicines and 113 for other medicines.

Over the years, the Group has been placing high importance on R&D and innovation, as well as through collaboration and imitation, to raise both R&D standards and efficiency. Regarding R&D as the lifeblood of the Group's development, the Group continues to devote into more resources. For the nine months ended 30 September, 2020, the total R&D expenditure of approximately RMB2.11 billion, which accounted for approximately 11.6% of the Group's revenue.

The Group also emphasizes on the protection of intellectual property rights. During the third quarter, the Group has received 37 authorized patent notices and filed 119 new patent applications. Cumulatively, the Group has obtained 879 invention patent approvals, 30 utility model patents and 115 apparel design patents.

Prospects
Looking ahead, the Group will continue to act proactively along with the varying characteristics of times and trends, accelerate its development of new drugs, and continuously optimize products in the R&D pipeline. The Group will also continue to optimize the layout of the Internet ecosystem, while promote the transformation and upgrade of organizational structure, so as to achieve a comprehensive strategic transformation in the Group as soon as possible, which in turn will lay a more solid foundation for the Group's long-term development and create long-term value for shareholders.

About Sino Biopharmaceutical Limited (HKEX:1177)
Sino Biopharmaceutical Limited is a leading, innovative R&D driven pharmaceutical conglomerate in the PRC. Its business encompasses a fully-integrated chain which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumors, liver diseases, respiratory system diseases, anti-infectious diseases and orthopedic diseases.

Sino Biopharm is a constituent stock of the following indices: MSCI Global Standard Indices – MSCI China Index, Hang Seng Index, Hang Seng Index – Commerce & Industry, Hang Seng Composite Index, Hang Seng Composite Industry Index – Consumer Goods, Hang Seng Composite LargeCap Index, Hang Seng Composite LargeCap & MidCap Index, Hang Seng China (Hong Kong-listed) 100 Index and Hang Seng Stock Connect Hong Kong Index. Sino Biopharm was ranked as one of "Asia's Fab 50 Companies" by Forbes Asia for three consecutive years in 2016, 2017 and 2018.



Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Captiva Verde Land Corp. Announces Solargram Farms’ Completion of Successful New Brunswick Outdoor Cannabis Harvest with One of the Highest Reported THC and Terpene Values in Canada

Coquitlam, British Columbia, Nov 30, 2020 – (ACN Newswire) – Captiva Verde Land Corp. (CSE: PWR) (the "Company"), is extremely pleased to announce that Solargram Farms Corporation ("Solargram"), a holder of a Federal Health Canada License to cultivate, test, harvest and sell cannabis, has successfully completed its first large scale cannabis outdoor farm harvest with record THC and terpene results.

First Year Harvest Results

The Solargram cannabis harvest began on September 17th and was completed on October 30th with final processing completed on November 27, 2020. The Solargram team is credited with a final harvest of approximately 13,000 plants over 350,000 square feet of outdoor farm grown canopy resulting in 15,000 kg of wet cannabis. This harvest is ranked as one of Canada's top single largest, and lowest cost outdoor legal cannabis crop in Canadian history and is also the largest outdoor cannabis crop ever grown and harvested in New Brunswick.

Very Low Cost of Production Results

Exceeding expectations, the year one total grow cost of production, including direct labor and direct materials, were CDN $0.05/gram wet; $0.22/gram dry which ranks as one of the top tier, lowest cost of cannabis production facilities in the Canadian cannabis industry.

Cannabis is a commodity within the CPG (consumer packaging goods) industry. Lowest cost and highest quality wins. Solargram is a major market disruptor and differentiator as its high quality, very low cost of production, allows its planned high cannabinoid full spectrum and distillate oil products to be sold at prices that are produced at a fraction of its competitors' cost of production. This competitive advantage will allow Solargram to become a leader in the Canadian cannabis market place commencing in 2021.

HIGH THC REPORTED – Independent Laboratory Test Results

Solargram produced and harvested approximately 35 genetics of which its R2 strain, representing 65% of its year one outdoor cannabis crop, produced a COA (certificate of analysis) from an independent laboratory supplier at 21.53% THC and 2.7% terpenes.

The independent THC laboratory results received for the top five genetics produced, representing the harvested crop include:

R2 (21.53%); Bitter Cherry Punch (18.81%); Gelatoz (17.59%);
Black Garlic (18.86%); New York Purple Diesel (19.66%)

These significant high THC results rival and/or exceed indoor cannabis grown facilities in Canada. Independent test results also validate the crop is pesticide and heavy metal free.

100% of the Solargram shares are held in an escrow account to be transferred to Captiva Verde in exchange for 35 Million Captiva Verde shares subject to a tight pooling agreement, and subject to Health Canada approving an in-process application by all the Captiva Verde Officers and Directors to pass a security clearance and CSE approval.

On Behalf of the Board of Directors
"Jeff Ciachurski"
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
E-mail: westernwind@shaw.ca

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/69147

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately

Malang, East Java, Indonesia, Nov 27, 2020 – (ACN Newswire) – Researchers from the Brawijaya University (UB) Medical School in Malang, East Java have developed DETAK, a smartphone application for patients with heart disease. The app works on an AI (artificial intelligence) algorithm, to provide early and accurate detection of heart disease, or acute coronary syndrome, and prevent delays in proper diagnose and treatment.

Acute coronary syndrome describes a host of conditions linked to the sudden, reduced flow of blood to the heart. One such condition is a myocardial infarction, or heart attack, in which cell death results and can lead to damaged or destroyed heart tissue. DETAK was designed to prevent these types of occurrences with early discovery.

"Apart from functioning as an early detection tool encouraging patients to seek treatment, DETAK serves to remind heart disease patients to take their medication and undergo medical checkups regularly," noted Mohammad Saifur Rohman, the lead researcher of cardiovascular study at the UB Medical School. The application also offers informative articles on heart disease and advice for maintaining a healthy heart.

Rohman drew attention to the importance of the early detection service in the application, since delay in the detection of heart disease is a main causal factors in the high number of heart attack cases resulting in death, citing data from the Dr. Saiful Anwar Hospital in Malang. He attributed this delay in detection mostly to a lack of knowledge and awareness of the symptoms of acute coronary syndrome.

For early detection of the ailment, patients using the DETAK app answer several questions related to chest pain they experience and will be notified on where to go to seek help. The app will direct users with high risk of acute coronary syndrome to hospitals with cardiologists on duty, while those with low risk of acute coronary syndrome will be directed to visit nearby health facilities with general practitioners on duty.

The DETAK application has already received the Indonesian Museum of Records (MURI) award, and will soon cover health facilities across Indonesia, with data collection in collaboration with the Indonesian Cardiologist Association (PERKI), Indonesian Medical Association (IDI) and other related facilities.

For further information, contact:
Universitas Brawijaya (UB) Public Relations
www.ub.ac.id and www.prasetya.ub.ac.id.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

DETAK by Brawijaya University Researchers detects Heart Disease Early and Accurately

Malang, East Java, Indonesia, Nov 27, 2020 – (ACN Newswire) – Researchers from the Brawijaya University (UB) Medical School in Malang, East Java have developed DETAK, a smartphone application for patients with heart disease. The app works on an AI (artificial intelligence) algorithm, to provide early and accurate detection of heart disease, or acute coronary syndrome, and prevent delays in proper diagnose and treatment.

Acute coronary syndrome describes a host of conditions linked to the sudden, reduced flow of blood to the heart. One such condition is a myocardial infarction, or heart attack, in which cell death results and can lead to damaged or destroyed heart tissue. DETAK was designed to prevent these types of occurrences with early discovery.

"Apart from functioning as an early detection tool encouraging patients to seek treatment, DETAK serves to remind heart disease patients to take their medication and undergo medical checkups regularly," noted Mohammad Saifur Rohman, the lead researcher of cardiovascular study at the UB Medical School. The application also offers informative articles on heart disease and advice for maintaining a healthy heart.

Rohman drew attention to the importance of the early detection service in the application, since delay in the detection of heart disease is a main causal factors in the high number of heart attack cases resulting in death, citing data from the Dr. Saiful Anwar Hospital in Malang. He attributed this delay in detection mostly to a lack of knowledge and awareness of the symptoms of acute coronary syndrome.

For early detection of the ailment, patients using the DETAK app answer several questions related to chest pain they experience and will be notified on where to go to seek help. The app will direct users with high risk of acute coronary syndrome to hospitals with cardiologists on duty, while those with low risk of acute coronary syndrome will be directed to visit nearby health facilities with general practitioners on duty.

The DETAK application has already received the Indonesian Museum of Records (MURI) award, and will soon cover health facilities across Indonesia, with data collection in collaboration with the Indonesian Cardiologist Association (PERKI), Indonesian Medical Association (IDI) and other related facilities.

For further information, contact:
Universitas Brawijaya (UB) Public Relations
www.ub.ac.id and www.prasetya.ub.ac.id.

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Brawijaya University develops GAD65 Rapid Test Diabetes Screening Kit

Malang, East Java, Indonesia, Nov 25, 2020 – (ACN Newswire) – Brawijaya University (UB) in Malang, East Java has developed an initial screening kit for diabetes. The Bioscience Rapid Test GAD65, developed by aresearch team led by Prof. Dr. Aulanni'am, drh, DES, is ready for commercialization and use in early screening for Type I Diabetes Mellitus, before measures and treatment are determined.

The reverse-flow immunochromatography-based detection kit identifies the presence of autoantibodies against GAD65, which indicate damage to beta-pancreatic cells, a marker for Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults (LADA).

Diabetes is a global health threat which can lead to complications that impact the quality of human life as well as substantially add to health costs for families and countries. Its increasing prevalence has raised concerns globally and prompted prevention efforts. Detecting and managing the condition through appropriate therapy is crucial for preventing deterioration in the condition of people suffering from the metabolic disease.

The Bioscience Rapid Test GAD65 is among the downstream products developed as part of the cooperation between Brawijaya University and state-owned pharmaceutical company PT Bio Farma (Persero). The preparation and production of the kit has involved various levels of research and testing, based on the consensus and regulations set by the World Health Organization (WHO) and the Indonesian Health Ministry.

The screening kit, which has a medical device distribution permit and meets the certification requirements for good medical device manufacturing from the Indonesian Ministry of Health, is ready to be produced and widely distributed and has been introduced to potential consumers in Spain, Taiwan, Japan, Saudi Arabia, Jordan, Madagascar, the Philippines, and Malaysia.

As part of the collaboration for the downstreaming process of the kit, Brawijaya University has been designated as the producer and PT Bio Farma as the main distributor of the patented product (ID. 0.022.556 B, 2009-Granted and P00201910578, 2019-Registered).

For further information, please contact:
Prof Dr. Aulanni'am, drh., DES
+62 812-3317-600
Public Relations,
Universitas Brawijaya
www.ub.ac.id
www.prasetya.ub.ac.id

Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SinoMab Commenced Construction of its China Headquarters

HONG KONG, Nov 23, 2020 – (ACN Newswire) – SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that SinoLink Pharma (Suzhou) Limited ("SinoLink Pharma"), a wholly-owned subsidiary of the Company, held a commencement ceremony of its new campus on 20 November in Suzhou Industrial Park, marking the official commencement of construction of SinoMab's China headquarters.



SinoMab China headquarters – SinoLink Pharma new campus commencement ceremony: Dr. Shui On Leung, the Executive Director, Chairman and CEO of SinoMab (right 3rd); Mr. Jing Qiang, the Executive Director and President of SinoMab (left 3rd)


SinoMab China headquarters – SinoLink Pharma new campus preview



SinoMab plans to invest 1 billion on the construction of the new campus of SinoLink Pharma in the next 2 years, which will become the Company's China headquarters. The total floor area amounted to 70,000 sq.m., including manufacturing shop, pilot plant, R&D center, quality inspection center, clinical study center, administration building, and biological reaction workshop with a capacity of 38,000 litres. The civil construction is expected to be completed by the end of 2022. Upon the completion of construction, the new campus will be able to produce 2.5 to 3.0 million bottles of mAb injection per year, representing a relatively high level in the industry.

SinoMab possesses an extensive drug candidate pipeline based on mAb, targeting on the treatments of various immunological diseases. The Company's flagship product, SM03, a potential global first-in-target anti-CD22 mAb for the treatment of Rheumatoid arthritis (RA), is currently in phase III clinical trials in China and expected to be commercialized by the end of 2021. One of the Company's key product, SN1011, has received the Investigational New Drug (IND) approval from the National Medical Products Administration of China. The IND approval would enable the Company to conduct comprehensive clinical development programs for the treatment of systemic lupus erythematosus (SLE) in China. And the Company plans to initiate the phase I clinical study in China in the near future.

Dr. Shui On Leung, the Executive Director, Chairman and Chief Executive Officer of SinoMab, said on the commencement ceremony: "SinoLink Pharma is SinoMab's headquarters of R&D, manufacturing, marketing and operation and the industrialization base in mainland China. The commencement of construction of the new campus marks the new start and journey of the Company's next 'Five Years' Plan'. As the smooth progress of the clinical trials of SM03, our flagship product, and SN1011 entering clinical stage, the Suzhou new campus will provide a platform and guarantee for our drug candidates' R&D progress and commercialization in the Chinese market acting as our headquarters in mainland China, R&D center and the most important manufacturing base. Looking forward, we will insist in independent innovation, accelerating R&D and commercialization and strengthening global cooperation and technical innovation based on our existed drug candidates and R&D capability, to become an important force in the global healthcare industry."

About SinoMab BioScience Limited
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Premier Integrated Platform in APAC to Develop Innovative Therapies for Oncology Antengene Corporation Limited Successfully Listed on Main Board of SEHK

HONG KONG, Nov 20, 2020 – (ACN Newswire) – Antengene Corporation Limited ("Antengene" or the "Company", together with its subsidiaries, the "Group", stock code: 6996.HK), a clinical-stage biopharmaceutical company with integrated drug discovery, clinical development, anchored in Asia-Pacific (APAC) with a global layout, is officially listed and commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK") today.



Antengene's listing ceremony in Shanghai:
Dr. Jay Mei, M.D., Ph.D., founder, Chairman and CEO (Left); Mr. Yiteng Liu, M.Sc., Chief Operating Officer (Right)



The total number of offer shares under the Global Offering amounts to 154,153,500 shares, with the final offer price determined at HK$18.08 per offer share. The net proceeds from the Global Offering to be received by the Company, after deduction of the underwriting fees and expenses paid and payable by the Company in connection with the Global Offering, are estimated to be approximately HK$2,635.9 million. The Hong Kong offer shares initially offered under the Hong Kong Public Offering have received satisfactory response, where the total number of valid applications amounted to approximately 264.76 times of the total number of Hong Kong offer shares initially available for subscription under the Hong Kong Public Offering. The offer shares initially offered under the International Offering have also been over-subscribed by approximately 13.5 times. Due to the heavy over-subscription under the Hong Kong Public Offering, the Company has adopted the claw back mechanism, through which part of the shares have been reallocated from the International Offering to the Hong Kong Public Offering. The final numbers of Hong Kong offer shares and International offer shares are respectively 77,077,000 and 77,076,500, each representing approximately 50% of the total number of the offer shares initially available under the Global Offering before any exercise of the over-allotment option.

Antengene, which focuses on innovative oncology medicines, adopts a differentiated combinatory and complementary R&D approach to discover, develop and commercialize global first-in-class, only-in-class and/or best-in-class therapies, in order to fully unlock their therapeutic potential. As of the latest practicable date, the Company had built a highly selective pipeline of 12 drug assets focused on oncology, in which one of the Company's core products, ATG-010 (selinexor) or XPOVIO (selinexor), is a first-in-class and only-in-class selective inhibitor of nuclear export (SINE) compound that inhibits the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus and selective induction of apoptosis in cancer cells. Currently, the Company has initiated two Phase II registrational clinical trials for R/R MM and R/R DLBCL and will leverage the data from the clinical trials carried out by Karyopharm (a global pharmaceutical company listed on NASDAQ) to submit the new drug application (NDA) for ATG-010 (selinexor) by 2021 directly in certain APAC countries or territories where NDA approval may be obtained without additional clinical trials, including Australia, Singapore, Hong Kong, South Korea, Taiwan and Thailand.

Dr. Jay Mei, M.D., Ph.D., founder of Antengene, has over 25 years of experience in clinical research and development of oncology therapeutics globally, focusing on the clinical R&D of oncology drugs in the United States and China. Other management members also have strong proven track records in the research, clinical development and commercialization of drugs around the globe as well as in financing and investments. Since Antengene's establishment, with its premier and experienced management team, it has received supports from industry-leading investors, including strategic investors such as Celgene, WuXi AppTec and Tigermed, and financial investors such as Fidelity, Blackrock, GIC, Hillhouse, Boyu Capital, FountainVest Partners and Qiming Venture Partners. Meanwhile, Fidelity, GIC, Blackrock, Boyu Capital, Cormorant, Hillhouse, Sequoia Capital China Growth, CRF Investment, Laurion Capital Master Fund and Octagon Investments are also the cornerstone investors in the Company's Global Offering.

Dr. Jay Mei, M.D., Ph.D., founder, Chairman and CEO of Antengene said, "Today marked a milestone in Antengene's development. Antengene's successful debut in the Hong Kong stock market shows global investors' profound recognition for our strategic model, growth potential, management team and product pipeline. We are so proud of it and would like to express our gratitude to investors for their trust in and support to Antengene. Setting off from a new starting point, we will seize the historical opportunity in the global novel drug development. By adopting the differentiated development approach and grasping the hot spots at the cutting edge of R&D, we will persevere in discovering, developing and commercializing novel oncology therapies with novel mechanisms so as to address unmet clinical needs in APAC and other parts of the world."

About Antengene Corporation Limited
Antengene Corporation Limited is a clinical-stage APAC biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide novel anti-cancer drugs to patients in APAC and around the world. Since its inception, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 9 IND approvals and has 9 ongoing cross-regional clinical trials in the APAC region. At Antengene, we focus on developing drug candidates with novel targets or MoAs and first-in-class potential to address significant unmet medical needs. The vision of Antengene is to "Treat Patients Beyond Borders" through research, development and commercialization of first-in-class/best-in-class therapeutics.


Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com